Nanostring's Prosigna Included in German Breast Cancer Rx Guidelines | GenomeWeb

NEW YORK (GenomeWeb) – Nanostring Technologies today announced that its Prosigna Breast Cancer Assay has been acknowledged within the treatment guidelines of the German Association of Gynecological Oncology (AGO).

The company also said that a recent decision by the German Joint Federal Committee (G-BA) has qualified German breast cancer patients with statutory government insurance as eligible for coverage for gene expression testing, such as that provided by Prosigna, to inform therapy decisions beginning April 1.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.